Precigen Inc (NAS:PGEN)
$ 0.7263 -0.0124 (-1.68%) Market Cap: 216.34 Mil Enterprise Value: 207.08 Mil PE Ratio: 0 PB Ratio: 3.91 GF Score: 45/100

Precigen Inc Endpoints Webinar: State of the Union for Advanced Therapies Transcript

Nov 09, 2023 / 05:00PM GMT
Release Date Price: $1.26
Anshul Mangal

And precision value and health have been advancing clinical and drug development, manufacturing and commercialization for the regenerative medicine sector for the past 10 years. Having been a partner to over advanced therapy organizations, we understand the complexities to bring a cell and gene therapy to market. Since our last day at the union addressed that advanced therapy landscape has changed significantly. During today's panel, we will be hearing from various experts on their respective companies. their perspectives on some of the roadblocks and opportunities in the cell and gene therapy development and the future of the sector moving forward. Now I'll briefly introduce our panelists. Joining us today are Dan Kirby, Chief Commercial Officer, Orca Bio. Welcome, Dan. Deborah Phippard, Chief Scientific Officer at Precision for Medicine. Helen Sabzevari, President and CEO of Precigen. Devyn Smith, CEO of Arbor Bio and Chad Salisbury, Senior Vice President of Project Pharma. All right. Let's get this rolling. To start, I would love to hear from each one of our panelists on their respective

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot